Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Роль антагонистов минералокортикоидных рецепторов в фармакотерапии хронической сердечной недостаточности
Роль антагонистов минералокортикоидных рецепторов в фармакотерапии хронической сердечной недостаточности
Батищева Г.А., Мубаракшина О.А., Сомова М.Н., Дронова Ю.М. Роль антагонистов минералокортикоидных рецепторов в фармакотерапии хронической сердечной недостаточности. Consilium Medicum. 2017; 19 (12): 33–37. DOI: 10.26442/2075-1753_19.12.33-37
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Представитель антагонистов минералокортикоидных рецепторов эплеренон демонстрирует высокую эффективность и безопасность в комплексном лечении пациентов с хронической сердечной недостаточностью. Препарат влияет на патогенез данного состояния, улучшает прогноз пациентов. Подтвержденные в клинических исследованиях эффективность и хорошая переносимость позволяют широко рекомендовать препарат эплеренона Эспиро в терапии кардиологических пациентов.
Ключевые слова: антагонисты минералокортикоидных рецепторов, хроническая сердечная недостаточность, инфаркт миокарда, эплеренон, Эспиро.
Key words: antagonists of mineralocorticoid receptors, chronic heart failure, myocardial infarction, eplerenone, Espiro.
Ключевые слова: антагонисты минералокортикоидных рецепторов, хроническая сердечная недостаточность, инфаркт миокарда, эплеренон, Эспиро.
________________________________________________
Key words: antagonists of mineralocorticoid receptors, chronic heart failure, myocardial infarction, eplerenone, Espiro.
Полный текст
Список литературы
1. Хроническая сердечная недостаточность: клинические рекомендации. Общество специалистов по сердечной недостаточности, Российское кардиологическое общество. М., 2016. / Khronicheskaia serdechnaia nedostatochnost': klinicheskie rekomendatsii. Obshchestvo spetsialistov po serdechnoi nedostatochnosti, Rossiiskoe kardiologicheskoe obshchestvo. M., 2016. [in Russian]
2. Фролова Э.Б., Яушев М.Ф. Современное представление о хронической сердечной недостаточности. Вестн. современной клин. медицины. 2013; 6 (2): 87–93. / Frolova E.B., Yaushev M.F. Sovremennoe predstavlenie o khronicheskoi serdechnoi nedostatochnosti. Vestn. sovremennoi klin. meditsiny. 2013; 6 (2): 87–93. [in Russian]
3. Упницкий А.А., Ерофеева С.Б., Белоусов Ю.Б. Фармакоэкономический анализ длительного лечения селективным бета-адреноблокатором бисопрололом пациентов с хронической сердечной недостаточностью. Consilium Medicum. 2001; 2 (2): 15–21. / Upnitskii A.A., Erofeeva S.B., Belousov Yu.B. Farmakoekonomicheskii analiz dlitel'nogo lecheniia selektivnym beta-adrenoblokatorom bisoprololom patsientov s khronicheskoi serdechnoi nedostatochnost'iu. Consilium Medicum. 2001; 2 (2): 15–21. [in Russian]
4. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Рос. кардиол. журн. 2016; 8: 7–13. / Fomin I.V. Khronicheskaia serdechnaia nedostatochnost' v Rossiiskoi Federatsii: chto segodnia my znaem i chto dolzhny delat'. Ros. kardiol. zhurn. 2016; 8: 7–13. [in Russian]
5. Беленков Ю.Н., Фомин И.В., Мареев В.Ю. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации: данные ЭПОХА–ХСН (часть 2). Журн. сердечная недостаточность. 2006; 7 (3): 3–7. / Belenkov Yu.N., Fomin I.V., Mareev V.Yu. i dr. Rasprostranennost' khronicheskoi serdechnoi nedostatochnosti v Evropeiskoi chasti Rossiiskoi Federatsii: dannye EPOKhA–KhSN (chast' 2). Zhurn. serdechnaia nedostatochnost'. 2006; 7 (3): 3–7. [in Russian]
6. Козиолова Н.А., Никонова Ю.Н., Шилова Я.Э. и др. Характеристика хронической сердечной недостаточности на фоне перманентной формы фибрилляции предсердий. Журн. сердечная недостаточность. 2013; 14 (1): 14–21. / Koziolova N.A., Nikonova Yu.N., Shilova Ya.E. i dr. Kharakteristika khronicheskoi serdechnoi nedostatochnosti na fone permanentnoi formy fibrilliatsii predserdii. Zhurn. serdechnaia nedostatochnost'. 2013; 14 (1): 14–21. [in Russian]
7. Хроническая сердечная недостаточность. Под ред. Ф.Т.Агеева и др. М.: ГЭОТАР-Медиа, 2010. / Khronicheskaia serdechnaia nedostatochnost'. Pod red. F.T.Ageeva i dr. M.: GEOTAR-Media, 2010. [in Russian]
8. Поляков Д.С., Фомин И.В., Валикулова Ф.Ю. и др. Эпидемиологическая программа ЭПОХА–ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА–Д–ХСН). Журн. сердечная недостаточность. 2016; 17 (6): 299–305. / Polyakov D.S., Fomin I.V., Valikulova F.Yu. i dr. Epidemiologicheskaia programma EPOKhA–KhSN: dekompensatsiia khronicheskoi serdechnoi nedostatochnosti v real'noi klinicheskoi praktike (EPOKhA–D–KhSN). Zhurn. serdechnaia nedostatochnost'. 2016; 17 (6): 299–305. [in Russian]
9. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (4-й пересмотр). Журн. сердечная недостаточность. 2013; 14 (7): 379 – 472. / Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (4-i peresmotr). Zhurn. serdechnaia nedostatochnost'. 2013; 14 (7): 379 – 472. [in Russian]
10. Бойцов С.А. Центральные и периферические механизмы патогенеза хронической сердечной недостаточности. Журн. сердечная недостаточность. 2005; 6 (2): 78–83. / Boitsov S.A. Tsentral'nye i perifericheskie mekhanizmy patogeneza khronicheskoi serdechnoi nedostatochnosti. Zhurn. serdechnaia nedostatochnost'. 2005; 6 (2): 78–83. [in Russian]
11. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689–97.
12. Behrenbeck T, Klarich KW, Shen W-K et al. In: Habermann TM, ed. Mayo Clinic Internal Medicine Board Review 2002–2003. Philadelphia, Pa: Lippincott Williams & Wilkins, 2002; p. 41–149.
13. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37 (27): 2129–200.
14. Ильина А.В., Мареев В.Ю., Герасимова В.В. и др. Эффективность терапии иАПФ фозиноприлом больных с ХСН в сочетании с СД типа 2 (по материалам исследования ФАСОН). Журн. сердечная недостаточность. 2005; 6 (5): 181–5. / Ilina A.V., Mareev V.Yu., Gerasimova V.V. i dr. Effektivnost' terapii iAPF fozinoprilom bol'nykh KhSN v sochetanii s SD tipa 2 (po materialam issledovaniia FASON). Zhurn. serdechnaia nedostatochnost'. 2005; 6 (5): 181–5. [in Russian]
15. The Consensus Trial Study Group. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. N Engl J Med 1987; 316 (23): 1429–35.
16. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003; 349 (20): 1893–906.
17. Vantrimpont P, Rouleau JL, Wun C-C et al. Additive Beneficial Effects of Beta-Blockers to Angiotensin-Converting Enzyme Inhibitors in the Survival and Ventricular Enlargement (SAVE) Study fn1fn1This study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montreal, Quebec, Canada. J Am Coll Cardiol 1997; 29 (2): 229–36.
18. Van Vliet A, Donker AJM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993; 71 (3): A21–8.
19. Pitt B, Remme W, Zannad F et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348 (14): 1309–21.
20. Borer JS, Bohm M, Ford I et al. Effect of ivabradine on recurrent hospitalization for worsening heart failurein patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 2012; 33 (22): 2813–20.
21. Hopper I, Easton K. Chronic heart failure. Aust Prescr 2017; 40 (4): 128–36.
22. Viengchareun S, Le Menuet D, Martinerie L et al. The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl Recept Signal 2007; 5: e012.
23. Cohn JN, Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006; 97 (10A): 4F–12F.
24. Guichard JL, Clark D 3rd, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013; 9: 321–31.
25. Cooper LB, Hammill BG, Peterson ED et al. Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circ Cardiovasc Qual Outcomes 2017; 10 (1). PII: e002946. DOI: 10.1161/CIRCOUTCOMES.116.002946
26. Kolkhof P, Bärfacker L. 30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 2017; 234 (1): T125–T140.
27. Delyani J, Myles K, Funder J. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens 1998; 11: 94A.
28. Witham MD, Gillespie ND, Struthers AD. Hyperkalemia after the publication of RALES. N Engl J Med 2004; 351 (23): 2448–50.
29. Zannad F, GattisStough W, Rossignol P et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33 (22): 2782–95.
30. Motta D, Cesano G, Pignataro A, Boero R. Severe hyperkalemia in patients referred to an emergency departement: the role of antialdosterone drugs and of renin-angiotensin system blockers. G Ital Nefrol 2017; 34 (1). PII: gin/34.1.11.
31. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21.
32. Zannad F, McMurray JJ, Drexler H et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010; 12 (6): 617–22.
33. Swedberg K, Zannad F, McMurray JJ et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59 (18): 1598–603.
2. Frolova E.B., Yaushev M.F. Sovremennoe predstavlenie o khronicheskoi serdechnoi nedostatochnosti. Vestn. sovremennoi klin. meditsiny. 2013; 6 (2): 87–93. [in Russian]
3. Upnitskii A.A., Erofeeva S.B., Belousov Yu.B. Farmakoekonomicheskii analiz dlitel'nogo lecheniia selektivnym beta-adrenoblokatorom bisoprololom patsientov s khronicheskoi serdechnoi nedostatochnost'iu. Consilium Medicum. 2001; 2 (2): 15–21. [in Russian]
4. Fomin I.V. Khronicheskaia serdechnaia nedostatochnost' v Rossiiskoi Federatsii: chto segodnia my znaem i chto dolzhny delat'. Ros. kardiol. zhurn. 2016; 8: 7–13. [in Russian]
5. Belenkov Yu.N., Fomin I.V., Mareev V.Yu. i dr. Rasprostranennost' khronicheskoi serdechnoi nedostatochnosti v Evropeiskoi chasti Rossiiskoi Federatsii: dannye EPOKhA–KhSN (chast' 2). Zhurn. serdechnaia nedostatochnost'. 2006; 7 (3): 3–7. [in Russian]
6. Koziolova N.A., Nikonova Yu.N., Shilova Ya.E. i dr. Kharakteristika khronicheskoi serdechnoi nedostatochnosti na fone permanentnoi formy fibrilliatsii predserdii. Zhurn. serdechnaia nedostatochnost'. 2013; 14 (1): 14–21. [in Russian]
7. Khronicheskaia serdechnaia nedostatochnost'. Pod red. F.T.Ageeva i dr. M.: GEOTAR-Media, 2010. [in Russian]
8. Polyakov D.S., Fomin I.V., Valikulova F.Yu. i dr. Epidemiologicheskaia programma EPOKhA–KhSN: dekompensatsiia khronicheskoi serdechnoi nedostatochnosti v real'noi klinicheskoi praktike (EPOKhA–D–KhSN). Zhurn. serdechnaia nedostatochnost'. 2016; 17 (6): 299–305. [in Russian]
9. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (4-i peresmotr). Zhurn. serdechnaia nedostatochnost'. 2013; 14 (7): 379 – 472. [in Russian]
10. Boitsov S.A. Tsentral'nye i perifericheskie mekhanizmy patogeneza khronicheskoi serdechnoi nedostatochnosti. Zhurn. serdechnaia nedostatochnost'. 2005; 6 (2): 78–83. [in Russian]
11. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689–97.
12. Behrenbeck T, Klarich KW, Shen W-K et al. In: Habermann TM, ed. Mayo Clinic Internal Medicine Board Review 2002–2003. Philadelphia, Pa: Lippincott Williams & Wilkins, 2002; p. 41–149.
13. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37 (27): 2129–200.
14. Ilina A.V., Mareev V.Yu., Gerasimova V.V. i dr. Effektivnost' terapii iAPF fozinoprilom bol'nykh KhSN v sochetanii s SD tipa 2 (po materialam issledovaniia FASON). Zhurn. serdechnaia nedostatochnost'. 2005; 6 (5): 181–5. [in Russian]
15. The Consensus Trial Study Group. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. N Engl J Med 1987; 316 (23): 1429–35.
16. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003; 349 (20): 1893–906.
17. Vantrimpont P, Rouleau JL, Wun C-C et al. Additive Beneficial Effects of Beta-Blockers to Angiotensin-Converting Enzyme Inhibitors in the Survival and Ventricular Enlargement (SAVE) Study fn1fn1This study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montreal, Quebec, Canada. J Am Coll Cardiol 1997; 29 (2): 229–36.
18. Van Vliet A, Donker AJM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993; 71 (3): A21–8.
19. Pitt B, Remme W, Zannad F et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348 (14): 1309–21.
20. Borer JS, Bohm M, Ford I et al. Effect of ivabradine on recurrent hospitalization for worsening heart failurein patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 2012; 33 (22): 2813–20.
21. Hopper I, Easton K. Chronic heart failure. Aust Prescr 2017; 40 (4): 128–36.
22. Viengchareun S, Le Menuet D, Martinerie L et al. The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl Recept Signal 2007; 5: e012.
23. Cohn JN, Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006; 97 (10A): 4F–12F.
24. Guichard JL, Clark D 3rd, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013; 9: 321–31.
25. Cooper LB, Hammill BG, Peterson ED et al. Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circ Cardiovasc Qual Outcomes 2017; 10 (1). PII: e002946. DOI: 10.1161/CIRCOUTCOMES.116.002946
26. Kolkhof P, Bärfacker L. 30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 2017; 234 (1): T125–T140.
27. Delyani J, Myles K, Funder J. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens 1998; 11: 94A.
28. Witham MD, Gillespie ND, Struthers AD. Hyperkalemia after the publication of RALES. N Engl J Med 2004; 351 (23): 2448–50.
29. Zannad F, GattisStough W, Rossignol P et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33 (22): 2782–95.
30. Motta D, Cesano G, Pignataro A, Boero R. Severe hyperkalemia in patients referred to an emergency departement: the role of antialdosterone drugs and of renin-angiotensin system blockers. G Ital Nefrol 2017; 34 (1). PII: gin/34.1.11.
31. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21.
32. Zannad F, McMurray JJ, Drexler H et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010; 12 (6): 617–22.
33. Swedberg K, Zannad F, McMurray JJ et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59 (18): 1598–603.
2. Фролова Э.Б., Яушев М.Ф. Современное представление о хронической сердечной недостаточности. Вестн. современной клин. медицины. 2013; 6 (2): 87–93. / Frolova E.B., Yaushev M.F. Sovremennoe predstavlenie o khronicheskoi serdechnoi nedostatochnosti. Vestn. sovremennoi klin. meditsiny. 2013; 6 (2): 87–93. [in Russian]
3. Упницкий А.А., Ерофеева С.Б., Белоусов Ю.Б. Фармакоэкономический анализ длительного лечения селективным бета-адреноблокатором бисопрололом пациентов с хронической сердечной недостаточностью. Consilium Medicum. 2001; 2 (2): 15–21. / Upnitskii A.A., Erofeeva S.B., Belousov Yu.B. Farmakoekonomicheskii analiz dlitel'nogo lecheniia selektivnym beta-adrenoblokatorom bisoprololom patsientov s khronicheskoi serdechnoi nedostatochnost'iu. Consilium Medicum. 2001; 2 (2): 15–21. [in Russian]
4. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Рос. кардиол. журн. 2016; 8: 7–13. / Fomin I.V. Khronicheskaia serdechnaia nedostatochnost' v Rossiiskoi Federatsii: chto segodnia my znaem i chto dolzhny delat'. Ros. kardiol. zhurn. 2016; 8: 7–13. [in Russian]
5. Беленков Ю.Н., Фомин И.В., Мареев В.Ю. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации: данные ЭПОХА–ХСН (часть 2). Журн. сердечная недостаточность. 2006; 7 (3): 3–7. / Belenkov Yu.N., Fomin I.V., Mareev V.Yu. i dr. Rasprostranennost' khronicheskoi serdechnoi nedostatochnosti v Evropeiskoi chasti Rossiiskoi Federatsii: dannye EPOKhA–KhSN (chast' 2). Zhurn. serdechnaia nedostatochnost'. 2006; 7 (3): 3–7. [in Russian]
6. Козиолова Н.А., Никонова Ю.Н., Шилова Я.Э. и др. Характеристика хронической сердечной недостаточности на фоне перманентной формы фибрилляции предсердий. Журн. сердечная недостаточность. 2013; 14 (1): 14–21. / Koziolova N.A., Nikonova Yu.N., Shilova Ya.E. i dr. Kharakteristika khronicheskoi serdechnoi nedostatochnosti na fone permanentnoi formy fibrilliatsii predserdii. Zhurn. serdechnaia nedostatochnost'. 2013; 14 (1): 14–21. [in Russian]
7. Хроническая сердечная недостаточность. Под ред. Ф.Т.Агеева и др. М.: ГЭОТАР-Медиа, 2010. / Khronicheskaia serdechnaia nedostatochnost'. Pod red. F.T.Ageeva i dr. M.: GEOTAR-Media, 2010. [in Russian]
8. Поляков Д.С., Фомин И.В., Валикулова Ф.Ю. и др. Эпидемиологическая программа ЭПОХА–ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА–Д–ХСН). Журн. сердечная недостаточность. 2016; 17 (6): 299–305. / Polyakov D.S., Fomin I.V., Valikulova F.Yu. i dr. Epidemiologicheskaia programma EPOKhA–KhSN: dekompensatsiia khronicheskoi serdechnoi nedostatochnosti v real'noi klinicheskoi praktike (EPOKhA–D–KhSN). Zhurn. serdechnaia nedostatochnost'. 2016; 17 (6): 299–305. [in Russian]
9. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (4-й пересмотр). Журн. сердечная недостаточность. 2013; 14 (7): 379 – 472. / Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (4-i peresmotr). Zhurn. serdechnaia nedostatochnost'. 2013; 14 (7): 379 – 472. [in Russian]
10. Бойцов С.А. Центральные и периферические механизмы патогенеза хронической сердечной недостаточности. Журн. сердечная недостаточность. 2005; 6 (2): 78–83. / Boitsov S.A. Tsentral'nye i perifericheskie mekhanizmy patogeneza khronicheskoi serdechnoi nedostatochnosti. Zhurn. serdechnaia nedostatochnost'. 2005; 6 (2): 78–83. [in Russian]
11. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689–97.
12. Behrenbeck T, Klarich KW, Shen W-K et al. In: Habermann TM, ed. Mayo Clinic Internal Medicine Board Review 2002–2003. Philadelphia, Pa: Lippincott Williams & Wilkins, 2002; p. 41–149.
13. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37 (27): 2129–200.
14. Ильина А.В., Мареев В.Ю., Герасимова В.В. и др. Эффективность терапии иАПФ фозиноприлом больных с ХСН в сочетании с СД типа 2 (по материалам исследования ФАСОН). Журн. сердечная недостаточность. 2005; 6 (5): 181–5. / Ilina A.V., Mareev V.Yu., Gerasimova V.V. i dr. Effektivnost' terapii iAPF fozinoprilom bol'nykh KhSN v sochetanii s SD tipa 2 (po materialam issledovaniia FASON). Zhurn. serdechnaia nedostatochnost'. 2005; 6 (5): 181–5. [in Russian]
15. The Consensus Trial Study Group. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. N Engl J Med 1987; 316 (23): 1429–35.
16. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003; 349 (20): 1893–906.
17. Vantrimpont P, Rouleau JL, Wun C-C et al. Additive Beneficial Effects of Beta-Blockers to Angiotensin-Converting Enzyme Inhibitors in the Survival and Ventricular Enlargement (SAVE) Study fn1fn1This study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montreal, Quebec, Canada. J Am Coll Cardiol 1997; 29 (2): 229–36.
18. Van Vliet A, Donker AJM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993; 71 (3): A21–8.
19. Pitt B, Remme W, Zannad F et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348 (14): 1309–21.
20. Borer JS, Bohm M, Ford I et al. Effect of ivabradine on recurrent hospitalization for worsening heart failurein patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 2012; 33 (22): 2813–20.
21. Hopper I, Easton K. Chronic heart failure. Aust Prescr 2017; 40 (4): 128–36.
22. Viengchareun S, Le Menuet D, Martinerie L et al. The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl Recept Signal 2007; 5: e012.
23. Cohn JN, Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006; 97 (10A): 4F–12F.
24. Guichard JL, Clark D 3rd, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013; 9: 321–31.
25. Cooper LB, Hammill BG, Peterson ED et al. Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circ Cardiovasc Qual Outcomes 2017; 10 (1). PII: e002946. DOI: 10.1161/CIRCOUTCOMES.116.002946
26. Kolkhof P, Bärfacker L. 30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 2017; 234 (1): T125–T140.
27. Delyani J, Myles K, Funder J. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens 1998; 11: 94A.
28. Witham MD, Gillespie ND, Struthers AD. Hyperkalemia after the publication of RALES. N Engl J Med 2004; 351 (23): 2448–50.
29. Zannad F, GattisStough W, Rossignol P et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33 (22): 2782–95.
30. Motta D, Cesano G, Pignataro A, Boero R. Severe hyperkalemia in patients referred to an emergency departement: the role of antialdosterone drugs and of renin-angiotensin system blockers. G Ital Nefrol 2017; 34 (1). PII: gin/34.1.11.
31. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21.
32. Zannad F, McMurray JJ, Drexler H et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010; 12 (6): 617–22.
33. Swedberg K, Zannad F, McMurray JJ et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59 (18): 1598–603.
________________________________________________
2. Frolova E.B., Yaushev M.F. Sovremennoe predstavlenie o khronicheskoi serdechnoi nedostatochnosti. Vestn. sovremennoi klin. meditsiny. 2013; 6 (2): 87–93. [in Russian]
3. Upnitskii A.A., Erofeeva S.B., Belousov Yu.B. Farmakoekonomicheskii analiz dlitel'nogo lecheniia selektivnym beta-adrenoblokatorom bisoprololom patsientov s khronicheskoi serdechnoi nedostatochnost'iu. Consilium Medicum. 2001; 2 (2): 15–21. [in Russian]
4. Fomin I.V. Khronicheskaia serdechnaia nedostatochnost' v Rossiiskoi Federatsii: chto segodnia my znaem i chto dolzhny delat'. Ros. kardiol. zhurn. 2016; 8: 7–13. [in Russian]
5. Belenkov Yu.N., Fomin I.V., Mareev V.Yu. i dr. Rasprostranennost' khronicheskoi serdechnoi nedostatochnosti v Evropeiskoi chasti Rossiiskoi Federatsii: dannye EPOKhA–KhSN (chast' 2). Zhurn. serdechnaia nedostatochnost'. 2006; 7 (3): 3–7. [in Russian]
6. Koziolova N.A., Nikonova Yu.N., Shilova Ya.E. i dr. Kharakteristika khronicheskoi serdechnoi nedostatochnosti na fone permanentnoi formy fibrilliatsii predserdii. Zhurn. serdechnaia nedostatochnost'. 2013; 14 (1): 14–21. [in Russian]
7. Khronicheskaia serdechnaia nedostatochnost'. Pod red. F.T.Ageeva i dr. M.: GEOTAR-Media, 2010. [in Russian]
8. Polyakov D.S., Fomin I.V., Valikulova F.Yu. i dr. Epidemiologicheskaia programma EPOKhA–KhSN: dekompensatsiia khronicheskoi serdechnoi nedostatochnosti v real'noi klinicheskoi praktike (EPOKhA–D–KhSN). Zhurn. serdechnaia nedostatochnost'. 2016; 17 (6): 299–305. [in Russian]
9. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (4-i peresmotr). Zhurn. serdechnaia nedostatochnost'. 2013; 14 (7): 379 – 472. [in Russian]
10. Boitsov S.A. Tsentral'nye i perifericheskie mekhanizmy patogeneza khronicheskoi serdechnoi nedostatochnosti. Zhurn. serdechnaia nedostatochnost'. 2005; 6 (2): 78–83. [in Russian]
11. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689–97.
12. Behrenbeck T, Klarich KW, Shen W-K et al. In: Habermann TM, ed. Mayo Clinic Internal Medicine Board Review 2002–2003. Philadelphia, Pa: Lippincott Williams & Wilkins, 2002; p. 41–149.
13. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37 (27): 2129–200.
14. Ilina A.V., Mareev V.Yu., Gerasimova V.V. i dr. Effektivnost' terapii iAPF fozinoprilom bol'nykh KhSN v sochetanii s SD tipa 2 (po materialam issledovaniia FASON). Zhurn. serdechnaia nedostatochnost'. 2005; 6 (5): 181–5. [in Russian]
15. The Consensus Trial Study Group. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. N Engl J Med 1987; 316 (23): 1429–35.
16. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003; 349 (20): 1893–906.
17. Vantrimpont P, Rouleau JL, Wun C-C et al. Additive Beneficial Effects of Beta-Blockers to Angiotensin-Converting Enzyme Inhibitors in the Survival and Ventricular Enlargement (SAVE) Study fn1fn1This study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montreal, Quebec, Canada. J Am Coll Cardiol 1997; 29 (2): 229–36.
18. Van Vliet A, Donker AJM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993; 71 (3): A21–8.
19. Pitt B, Remme W, Zannad F et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348 (14): 1309–21.
20. Borer JS, Bohm M, Ford I et al. Effect of ivabradine on recurrent hospitalization for worsening heart failurein patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 2012; 33 (22): 2813–20.
21. Hopper I, Easton K. Chronic heart failure. Aust Prescr 2017; 40 (4): 128–36.
22. Viengchareun S, Le Menuet D, Martinerie L et al. The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl Recept Signal 2007; 5: e012.
23. Cohn JN, Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006; 97 (10A): 4F–12F.
24. Guichard JL, Clark D 3rd, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013; 9: 321–31.
25. Cooper LB, Hammill BG, Peterson ED et al. Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circ Cardiovasc Qual Outcomes 2017; 10 (1). PII: e002946. DOI: 10.1161/CIRCOUTCOMES.116.002946
26. Kolkhof P, Bärfacker L. 30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 2017; 234 (1): T125–T140.
27. Delyani J, Myles K, Funder J. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens 1998; 11: 94A.
28. Witham MD, Gillespie ND, Struthers AD. Hyperkalemia after the publication of RALES. N Engl J Med 2004; 351 (23): 2448–50.
29. Zannad F, GattisStough W, Rossignol P et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33 (22): 2782–95.
30. Motta D, Cesano G, Pignataro A, Boero R. Severe hyperkalemia in patients referred to an emergency departement: the role of antialdosterone drugs and of renin-angiotensin system blockers. G Ital Nefrol 2017; 34 (1). PII: gin/34.1.11.
31. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21.
32. Zannad F, McMurray JJ, Drexler H et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010; 12 (6): 617–22.
33. Swedberg K, Zannad F, McMurray JJ et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59 (18): 1598–603.
Авторы
Г.А.Батищева, О.А.Мубаракшина*, М.Н.Сомова, Ю.М.Дронова
ФГБОУ ВО «Воронежский государственный медицинский университет им. Н.Н.Бурденко» Минздрава России. 394036, Россия, Воронеж, ул. Студенческая, д. 10
*mubarakshina@mail.ru
Voronezh State Medical University of the Ministry of Health of the Russian Federation. 394036, Russian Federation, Voronezh, ul. Studencheskaia, d. 10
mubarakshina@mail.ru
ФГБОУ ВО «Воронежский государственный медицинский университет им. Н.Н.Бурденко» Минздрава России. 394036, Россия, Воронеж, ул. Студенческая, д. 10
*mubarakshina@mail.ru
________________________________________________
Voronezh State Medical University of the Ministry of Health of the Russian Federation. 394036, Russian Federation, Voronezh, ul. Studencheskaia, d. 10
mubarakshina@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.